On controlling stochastic sensitivity of oscillatory systems

For a nonlinear oscillatory stochastic system, we study the control problem for the variance of random trajectories around a deterministic cycle. To describe the range of random trajectories, we use the method of stochastic sensitivity functions. We consider the problem of designing a given stochastic sensitivity function, discuss problems of controllability and reachability. Complete stochastic controllability is only possible when the control's dimension coincides with the system's dimension. Otherwise, the design problem becomes ill-posed. To solve it, we propose a regularization method that lets us produce a given stochastic sensitivity function with any given precision. The efficiency of the proposed approach is demonstrated with the example of controlling stochastic oscillations in a brusselator model. © 2013 Pleiades Publishing, Ltd

The pattern of female genital hormonal disease in juvenile myoclonic epilepsy

Objective: to reveal and investigate hormonal characteristics in women of childbearing age in juvenile myoclonic epilepsy (JME).Patients and methods. The concentrations of sex steroid and tropic hormones were analyzed in 48 women of childbearing age who suffered from JME and received monotherapy or bitherapy with antiepileptic drugs (AEDs) for more than a year. For comparison of their values, a control group included 15 healthy women who did not take AEDs. Results and discussion. 66.7% of the patients were found to have ovarian hormonal dysfunction characterized by a significant increase in the level of luteinizing hormone and testosterone in the follicular phase of the cycle and a decrease in that of progesterone in the luteal phase compared with the control group. The hormonal deviations were influenced by disease duration and age-related onset in JME. Generalized tonicclonic seizures concurrent with myoclonic ones, bitherapy, and disease onset before menarche and in the period of the menstrual cycle favored the  development of hormonal deviations to a greater extent than myoclonic seizures only, monotherapy, and disease onset after the establishment of the cycle. Valproates were most commonly used in the therapy of JME; however, there were no significant differences in the hormonal deficiencies when different chemical groups of AEDs were administered

Prevalence of chronic HCV infection in patients with type 2 diabetes mellitus in Russia

BACKGROUND: The poor outcomes of chronic hepatitis C (CHC) and type 2 diabetes determine the socio-economic significance of the combined pathology since they lead to premature death. The proportion of patients with type 2 diabetes with markers of viral hepatitis (VH) in the Russian Federation is not known, which does not allow us to estimate the burden for the state of this medical problem.OBJECTIVE: Assessment of the prevalence of concomitant pathology, HCV infection and type 2 diabetes, as well as the proportion of severe liver damage in its structure, according to the analysis of the primary medical records of four Moscow hospitals.MATERIALS AND METHODS: A retrospective analysis of the medical records of patients with HCV infection and diabetes mellitus, who admitted at different periods to four hospitals in Moscow, was carried out, as well as a total examination for the presence of anti-HCV in the blood of all patients with diabetes who were admitted within a certain period to the endocrinology department of a multidisciplinary hospital. Additionally, to determine the proportion of patients with liver cirrhosis (LC), an additional examination of patients with this combined pathology was carried out in accordance with the standards for the diagnosis of hepatitis C.RESULTS: In total, according to data from 4 hospitals in Moscow, over a certain period, 2% (105/5298) of diabetes patients with anti-HCV in their blood were identified. Sex ratio for men: women = 54 (51%): 51 (49%). Patients aged 50–69 years prevailed — 70% (74/105). Seroprevalence of HCV in cohorts of patients with type 2 diabetes according to the analysis in 3 health facilities: 0.9% (20/2196), 1.9% (8/432), 1.9% (28/1500). A significant drawback was revealed that did not allow assessing the true seroprevalence of HCV: not all patients were hospitalized with the results of a VH test, and not all of them were assigned an examination for VH markers if it was not performed before hospitalization. The proportion of type 2 diabetes patients with anti-HCV in the blood according to the results of total screening (3.7%; 16/432) became comparable to the proportion of type 2 diabetes patients among patients with CHC admitted to an infectious hospital (4.2%; 49 / 1170). The proportion of patients with LC according to the analysis of the medical records of the infectious hospital is 65% (32/49), in the group of endocrinological patients with additional examination it is 18% (13/71).CONCLUSION: For the first time in the Russian Federation, data were obtained on the prevalence of HCV infection in combination with type 2 diabetes. The results of the study indicate the need to develop effective screening programs to detect active HCV infection in the group of patients with diabetes, as well as patients among them with severe hepatic fibrosis for the timely conduct of highly effective antiviral therapy, which will prevent poor outcomes in a separate perspective

The first combined russian experience of using perampanel in children and adolescents with epilepsy in everyday clinical practice

Background. Real world data help to provide more information on the effects and tolerability of therapy. However, data on the use of perampanel in Russian population of children remain limited. aim. To conduct a retrospective analysis of perampanel efficacy and tolerability in children and adolescents with epilepsy in real clinical practice. Materials and methods. A total of 106 children aged 4–18 years receiving perampanel as part of combination therapy for epilepsy were observed at 18 centers. Seizure frequency at 1–3, after 6 and 12 months of treatment, presence and type of adverse events (AEs) were analyzed. The main assessed efficacy parameters were seizure control, significant (≥50 %) decrease in seizure frequency. All other outcomes (<50 % decrease, no change or increased seizure frequency) were considered to be no effect. The assessed safety parameters were the percentage of patients with or without AEs and the percentage of perampanel withdrawals due to AEs. results. We defined 3 age groups for comparison: children 4–6, 7–11 and 12–17 years old. Perampanel efficacy was 69 % (seizure control – 23.6 %, ≥50 % decrease in seizure frequency – 45.3 %). The mean duration of the effect was 7.3 ± 4.1 months. No significant difference in efficacy between age groups was found. However, some greater efficacy of perampanel was noted in adolescents: absence of effect in the form of remission or significant decrease in seizures frequency was noted only in 25.5 %, with 40 % in children 4–11 years old. Among those with inefficacy, 3.8 % reported seizure aggravation. AEs occurred in only 23 % of patients, with the least frequent occurrence in adolescents (11.8 %) and the most frequent in children aged 7–11 years (40 %). The most frequent AEs was sluggishness and/or drowsiness. Discontinuation of perampanel due to AEs was required in 7.6 %. Conclusion. Perampanel has demonstrated high efficacy and good tolerability in real clinical practice among children from 4 years of age and adolescents with partial (focal) and secondary generalized seizures. The AEs that developed were not serious and very rarely led to withdrawal of the therapy. The results are comparable to those of phase III studies and previous real-world data. The usage of perampanel in children with primary generalized seizures should be further investigated. © 2022 ABV-Press Publishing House. All rights reserved.EisaiО.А. Рахманина / O.A. Rakhmanina: https://orcid.org/0000-0001-9218-2531 И.В. Волков / I.V. Volkov: https://orcid.org/0000-0002-7816-7535 О.К. Волкова / O.K. Volkova: https://orcid.org/0000-0003-3314-3895 Ю.А. Александров / Yu.A. Aleksandrov: https://orcid.org/0000-0003-3887-5219 М.В. Бархатов / M.V. Barkhatov: https://orcid.org/0000-0002-6372-4677 И.С. Бахтин / I.S. Bakhtin: https://orcid.org/0000-0003-3600-687X Г.М. Бережная / G.M. Berezhnaya: https://orcid.org/0000-0003-3917-422X А.Ю. Карась / A.Yu. Karas: https://orcid.org/0000-0001-9089-9627 Д.В. Морозов / D.V. Morozov: https://orcid.org/0000-0003-4389-9143 И.С. Бахтин / I.S. Bakhtin: https://orcid.org/0000-0003-3600-687X Т.Р. Томенко / T.R. Tomenko: https://orcid.org/0000-0002-0652-1996 Ж.М. Цоцонава / Zh.M. Tsotsonava: https://orcid.org/0000-0003-3275-5099 Конфликт интересов и финансирование. Публикация подготовлена при финансовой поддержке компании «Эйсай». Авторы несут полную ответственность за содержание статьи и редакционные решения. Conflict of interest and funding. This publication was funded by Eisai. The authors are fully responsible for the content of the article and editorial decisions

Lechenie katarakty u deteys sakharnym diabetom 1 tipa

Цель. Изучение результатов хирургического лечения диабетической катаракты у детей. Материалы и методы. Проведено обследование и лечение 13 детей (24 глаза) с осложненной катарактой и сахарным диабетом 1 типа. Обследование включало визометрию, биомикроскопию, прямую офтальмоскопию с фоторегистрацией на фундус камере ?Canon?, флуоресцентную ангиографию, электроретинографию, зрительные вызванные корковые потенциалы. Результаты. После удаления катаракты у 2 детей на 2?3-й день после операции мы наблюдали декомпенсацию заболевания. После первичной имплантации (20 глаз) наблюдалось 17 случаев вторичной катаракты (85%). У 2 из 11 оперированных детей (4 глаза) после удаления катаракты с имплантацией ИОЛ выявлена диабетическая ретинопатия (ДР), не диагностированная до операции. Выводы. Для получения достаточно высоких визуальных результатов при экстракции диабетической катаракты необходима взаимосвязанная работа эндокринологов и офтальмологов. Хирургическое лечение катаракты с имплантацией интраокулярных линз у детей с СД 1 типа обеспечивает достаточно высокие функциональные результаты ? оптимальным является применение гибких гидрофобных линз

Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2

Chronic hepatitis C virus (HCV) infection is a leading cause of liver related morbidity and mortality. In many countries, there is a lack of comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished data and expert consensus were used to determine key parameters, including prevalence, viremia, genotype and the number of patients diagnosed and treated. In this study of 15 countries, viremic prevalence ranged from 0.13% in the Netherlands to 2.91% in Russia. The largest viremic populations were in India (8 666 000 cases) and Russia (4 162 000 cases). In most countries, males had a higher rate of infections, likely due to higher rates of injection drug use (IDU). Estimates characterizing the infected population are critical to focus screening and treatment efforts as new therapeutic options become availabl

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios was considered: (i) increased treatment efficacy while holding the treated population constant and (ii) increased treatment efficacy and increased annual treated population. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. In most countries, the annual treated population had to increase several fold to achieve the largest reductions in HCV-related morbidity and mortality. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. In most of the studied countries, the majority of patients were born between 1945 and 198

The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieve

The present and future disease burden of hepatitis C virus (HCV) infections with today&apos;s treatment paradigm - volume 2

Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 countries to quantify and characterize the viremic population, as well as estimate the number of new infections and HCV related deaths from 2013 to 2030. Expert consensus was used to determine current treatment levels and outcomes in each country. In most countries, viremic prevalence has already peaked. In every country studied, prevalence begins to decline before 2030, when current treatment levels were held constant. In contrast, cases of advanced liver disease and liver related deaths will continue to increase through 2030 in most countries. The current treatment paradigm is inadequate if large reductions in HCV related morbidity and mortality are to be achieved